Hemodynamic and Humoral Effects of Low-Dose Aspirin in Treated and Untreated Essential Hypertensive Patients

References

• Patak R V, Mookerjee B K, Bentzel C J, Hysert P E, Babej M, Lee J B. Antagonism of the effects of furosemide by indomethacin in normal and hypertensive men. Prostaglandin 1975; 10: 4, 649–59
   Web of Science ®Google Scholar
• Chalmers J P, West M J, Wing L MH, Bune A JC, Graham J R. Effects of indomethacin, sulindac, naproxen, aspirin, and paracetamol in treated hypertensive patients. Clin Exp Hypertens—Theory and Practice 1984; A6: 1077–93
   Google Scholar
• Brown J, Dollery C, Valdes G. Interaction of nonsteroidal anti-inflammatory drugs with antihypertensive and diuretic agents. Am J Med 1986; 81(Suppl 2B)43–57
   PubMed Web of Science ®Google Scholar
• Salvetti A, Arzilli F, Pedrinelli R, Beggi P, Motolese M. Interaction between oxprenolol and indomethacin on blood pressure in essential hypertensive patients. Eur J Clin Pharmacol 1982; 22: 197–201
   PubMed Web of Science ®Google Scholar
• Watkins J, Abbott E C, Hensby C N, Webster J, Dollery C T. Attenuation of hypotensive effect of propranolol and thiazide diuretics by indomethacin. BMJ 1980; 281: 702–5
   PubMed Web of Science ®Google Scholar
• Durao V, Prata M M, Goncalves L MP. Modification of antihypertensive effect of β-adrenoceptor-blocking agents by inhibition of endogenous prostaglandin synthesis. Lancet 1977; ii: 1005–7
   Google Scholar
• Salvetti A, Pedrinelli R, Magagna A, Abdel-Haq B. The influence of indomethacin on some pharmacological actions of atenolol. Prostaglandins and the Kidney, M J Dunn, C Patrono, G A Cinotti. Plenum, New York 1982; 287–95
   Google Scholar
• Rubin P, Jackson G, Blaschke T. Studies on the clinical pharmacology of prazosin II: the influence of indomethacin and of propranolol on the action and disposition of prazosin. Br J Pharmacol 1980; 10: 33–9
   Web of Science ®Google Scholar
• Salvetti A, Pedrinelli R, Magagna A, Ugenti P. Differential effects of selective and non-selective prostaglandin-synthesis inhibition on the pharmacological responses to captopril in patients with essential hypertension. Clin Sci 1982; 63: 261s–3
   Web of Science ®Google Scholar
• Salvetti A, Abdel-Haq B, Magagna A, Pedrinelli R. Indomethacin reduces the antihypertensive action of enalapril. Clin Exp Hypertens—Theory and Practice 1987; A9: 559–67
   Google Scholar
• Wong D G, Spence J D, Lamki L, Freeman D, Mc Donald J WD. Effect of non-steroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics. Lancet 1986; i: 997–1001
   Google Scholar
• Abdel-Haq B, Magagna A, Favilla S, Salvetti A. Hemodynamic and humoral interactions between perindopril and indomethacin in essential hypertensive subjects. J Cardiovasc Pharmacol 1991; 18(Suppl 7)s33–6
   Google Scholar
• Arrighi P, Lucarini A R, Abdel-Haq B, et al. The role of prostaglandins in the systemic and renal hemodynamic actions of lisinopril. High Blood Press 1993; 2: 31–6
   Google Scholar
• Gerber J G. Indomethacin-induced rises in blood pressure. Ann Intern Med 1983; 99: 555–8
   PubMed Web of Science ®Google Scholar
• Salvetti A, Pedrinelli R. Pharmacological evaluation of prostaglandins and their interaction with renin secretion in human hypertension. Endocrinology of hypertension, F Mantero, E G Biglieri, C RW Edwards. Academic Press, London 1982; 243–56
   Google Scholar
• Lewis R V, Mc Lay J, Maclean D, et al. The effects of indomethacin and sulindac upon the blood pressure of individuals with untreated labile or mild hypertension. J Hum Hypertens 1989; 3: 233–7
   PubMed Web of Science ®Google Scholar
• Magagna A, Abdel-Haq B, Favilla S, Giovannetti R, Salvetti A. Indomethacin raises blood pressure in untreated essential hypertensives: a double-blind randomly allocated study versus placebo. J Hypertens 1991; 9(Suppl 6)S242–3
   Google Scholar
• UK-TIA Study Group. United Kingdom transient ischemic attack (UK-TIA) aspirin-trial: interim results. BMJ 1988; 296: 316–20
   PubMed Web of Science ®Google Scholar
• Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991; 325: 1261–6
   PubMed Web of Science ®Google Scholar
• SALT Collaborative Group. Swedish aspirin low-dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischemic events. Lancet 1991; 338: 1345–9
   PubMed Web of Science ®Google Scholar
• Hansson L, for the HOT Study Group. The hypertension optimal treatment study (the HOT study). Blood Pressure 1993; 2: 62–8
   PubMedGoogle Scholar
• Patrono C. Radioimmunoassay of serum thromboxane B2: a simple method to assess pharmacological effects on platelet function. Advances in prostaglandin and thromboxane research. 1980; 6: 187–97
   PubMedGoogle Scholar
• Hassid A, Dunn M J. Microsomal prostaglandin biosynthesis of human kidney. J Biol Chem 1990; 255: 2472–5
   Google Scholar
• Ciabattoni G, Pugliese F, Cinotti G A, Patrono C. Renal effects of anti-inflammatory drugs. Eur J Rheumatol 1980; 3: 210–21
   Web of Science ®Google Scholar
• Zucchelli G C, Malvano R, Salvetti A. Control of the enzyme system in plasma renin activity measurement by angiotensin I radioimmunoassay. J Nucl Biol Med 1973; 17: 187–95
   PubMedGoogle Scholar
• Vane J R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature (New Biol) 1971; 231: 232–5
   PubMedGoogle Scholar
• Moncada S, Vane J R. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2 and prostacyclin. Pharmacol Rev 1979; 30: 293–331
   Web of Science ®Google Scholar
• Clarke R J, Mayo G, Price P, FitzGerald G A. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med 1991; 325: 1137–41
   PubMed Web of Science ®Google Scholar
• Salvetti A, Arzilli F, Baccini C. The effect of a beta-blocker on plasma renin activity of hypertensive patients. J Nucl Biol Med 1973; 17: 142–50
   PubMedGoogle Scholar